Related Experiment Video
Updated: Jul 28, 2025
07:59
Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol
Published on: July 28, 2018
11.2K
[Combination diuretic therapy in heart failure].
Karen Massop1,2, C Kees Kramers1
1Radboudumc, afd. Klinische Farmacologie, Nijmegen.
Nederlands Tijdschrift Voor Geneeskunde
|May 31, 2023
Summary
Adding acetazolamide to loop diuretics improved decongestion in patients with decompensated heart failure. This combination therapy showed increased efficacy without apparent additional side effects, offering a promising treatment option.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- Loop diuretics are essential for managing volume overload in decompensated heart failure.
- Incomplete decongestion often occurs due to compensatory sodium resorption in the nephron.
- Combining diuretics can overcome these compensatory mechanisms.
Purpose of the Study:
- To evaluate the efficacy and safety of adding acetazolamide to loop diuretics for treating decompensated heart failure.
- To assess if acetazolamide enhances decongestion rates compared to loop diuretics alone.
Main Methods:
- A multicenter, double-blind, randomized, placebo-controlled study.
- Patients with decompensated heart failure received either loop diuretics plus acetazolamide or loop diuretics plus placebo.
- Decongestion rates and side effects were monitored.
Main Results:
- The addition of acetazolamide to loop diuretics resulted in a higher rate of decongestion.
- No significant increase in adverse side effects was observed with the combination therapy.
- Acetazolamide demonstrated potential in improving decongestion efficacy.
Conclusions:
- Adding acetazolamide to loop diuretics is a potentially effective strategy for achieving rapid decongestion in decompensated heart failure.
- This combination therapy appears safe and warrants consideration in clinical practice.
- Further research may solidify acetazolamide's role in heart failure management.
Related Concept Videos
01:22Heart Failure Drugs: Diuretics
430
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
430
01:22Heart Failure VI: Adjunct Therapies
17
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
17
01:30Heart Failure V: Medical Management
16
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
16
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
471
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
471
01:22Heart Failure Drugs: β-Blockers
394
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
394
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
774
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
774